ROCKVILLE, Md., July 25,
2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX)
today announced that it will host a conference call on Thursday, August 1, 2024, at 4:30 p.m. ET to discuss its financial results for
the second quarter ended June 30,
2024, and recent operational highlights.
To access the live call by phone, dial (646) 307-1963 (domestic)
or (800) 715-9871 (international) and enter the passcode 4849384.
To access a live or recorded webcast of the call, please visit the
Investors section of the REGENXBIO website at www.regenxbio.com.
The recorded webcast will be available for approximately 30 days
following the call. Those who plan on participating are advised to
join 15 minutes prior to the start time.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. Since its founding in 2009, REGENXBIO has pioneered the
development of AAV Therapeutics, an innovative class of gene
therapy medicines. REGENXBIO is advancing a pipeline of AAV
Therapeutics for retinal and rare diseases, including ABBV-RGX-314
for the treatment of wet AMD and diabetic retinopathy, being
developed in collaboration with AbbVie, RGX-202 for the treatment
of Duchenne and RGX-121 for the treatment of MPS II. Thousands of
patients have been treated with REGENXBIO's AAV Therapeutic
platform, including Novartis' ZOLGENSMA for children with spinal
muscular atrophy. Designed to be one-time treatments, AAV
Therapeutics have the potential to change the way healthcare is
delivered for millions of people. For more information, please
visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-august-1-to-discuss-second-quarter-2024-financial-results-and-recent-operational-highlights-302206370.html
SOURCE REGENXBIO Inc.